Frankfurt
03.10.25 | 08:21
0,073 Euro
+0,82 % +0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | NextCell Pharma AB: NextCell Pharma AB announces CFO transition | 73 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company's CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout... ► Artikel lesen | |
| 24.07. | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 3 2024/2025 | 126 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 - May 31, 2025. This English version of the Interim Report is a translation of the Swedish version.... ► Artikel lesen | |
| 14.07. | NEXTCELL PHARMA AB: NextCell Highlighted in FUJIFILM's Strategic Vision, According to GEN | 2 | Cision News | ||
| 13.06. | NextCell Pharma AB: All Patients Successfully Treated in ProTrans-Young Study | 358 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") announces today that all patients in the ongoing ProTrans-Young clinical trial have now successfully been treated. This milestone marks the completion... ► Artikel lesen | |
| 02.06. | NEXTCELL PHARMA AB: NextCell Pharma announces outcome of exercise of TO2 and resolves on directed share issues to guarantors | 1 | Cision News | ||
| 28.05. | NEXTCELL PHARMA AB: NextCell Pharma receives additional declarations of intent regarding exercise of TO2 | 1 | Cision News | ||
| 28.05. | NEXTCELL PHARMA AB: Angela Vollstedt joins NextCell Pharma's Board of Advisors to Strengthen Scientific and Manufacturing Strategy Ahead of Licensing Discussions | 1 | Cision News | ||
| 26.05. | NextCell Pharma AB: NextCell Receives US Patent for MSC Prediction Algorithm | 349 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the issuance of a US patent titled "MSC Prediction Algorithm" by the United States Patent and Trademark Office (USPTO). The patent... ► Artikel lesen | |
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 23.05. | NEXTCELL PHARMA AB: NextCell Pharma receives declarations of intent, subscription undertakings and top guarantees regarding exercise of TO2 | 1 | Cision News | ||
| 20.05. | NextCell, Fujifilm Irvine Scientific Enter Strategic Pact | 4 | Contract Pharma | ||
| 20.05. | NextCell Pharma AB: NextCell announces strategic collaboration with Fujifilm Irvine Scientific | 716 | GlobeNewswire (Europe) | NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells... ► Artikel lesen | |
| 19.05. | NEXTCELL PHARMA AB: Eric Strati Joins NextCell Pharma's Board of Advisors to Support Commercial Strategy for ProTrans | 1 | Cision News | ||
| 16.05. | NEXTCELL PHARMA AB: The exercise period for NextCell Pharma's warrants of series TO2 begins today | - | Cision News | ||
| 15.05. | NEXTCELL PHARMA AB: Eight-Year-Old Hugo - Living with Type 1 Diabetes and Participating in the ProTrans Study | 1 | Cision News | ||
| 07.05. | NEXTCELL PHARMA AB: Study published in Nature Medicine shows promising results in Alzheimer's disease - supports the development of ProTrans at NextCell | 2 | Cision News | ||
| 25.04. | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 2 2024/2025 | 125 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 - February 28, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 24.04. | NEXTCELL PHARMA AB: NextCell presents detailed analysis of the administrative report from ProTrans-Young | 2 | Cision News | ||
| 23.04. | NEXTCELL PHARMA AB: NextCell Presents Quarterly Report | 4 | Cision News | ||
| 15.04. | NextCell Pharma AB: NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward | 143 | GlobeNewswire (Europe) | NextCell Pharma ("the company" or "NextCell") has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the... ► Artikel lesen | |
| 07.04. | NEXTCELL PHARMA AB: Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young | 1 | Cision News |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
| CG ONCOLOGY | 39,820 | -0,09 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
| IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts | ||
| JANUX THERAPEUTICS | 24,000 | +3,05 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,310 | +0,29 % | ARS Pharma secures $250M loan to accelerate Neffy rollout | ||
| BIONTECH | 90,45 | +0,06 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,770 | -2,25 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| EVOTEC | 6,744 | +2,00 % | Rheinmetall Aktie: Große Chance? - ABO Energy, Evotec, Funkwerk, MPC Capital und Redcare Pharmacy im Marktbericht Börse Frankfur | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 8,470 | +13,54 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| LENZ THERAPEUTICS | 48,740 | +0,87 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,18 | +10,89 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 47,010 | +6,41 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |
NEXTCELL PHARMA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,073 Euro und damit +0,82 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.